0A4W Stock Overview
A biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0A4W from our risk checks.
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.07 |
| 52 Week High | US$33.96 |
| 52 Week Low | US$14.57 |
| Beta | 0.40 |
| 11 Month Change | 6.11% |
| 3 Month Change | -12.91% |
| 1 Year Change | -34.00% |
| 33 Year Change | -35.63% |
| 5 Year Change | n/a |
| Change since IPO | -61.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4W | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 7.6% | -1.6% | 0.2% |
| 1Y | -34.0% | -25.9% | 7.4% |
Return vs Industry: 0A4W underperformed the UK Biotechs industry which returned -25.9% over the past year.
Return vs Market: 0A4W underperformed the UK Market which returned 7.4% over the past year.
Price Volatility
| 0A4W volatility | |
|---|---|
| 0A4W Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A4W has not had significant price volatility in the past 3 months.
Volatility Over Time: 0A4W's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 610 | Steve Davis | www.acadia.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
| 0A4W fundamental statistics | |
|---|---|
| Market cap | US$2.56b |
| Earnings (TTM) | -US$1.71m |
| Revenue (TTM) | US$813.81m |
3.3x
P/S Ratio-1,582x
P/E RatioIs 0A4W overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4W income statement (TTM) | |
|---|---|
| Revenue | US$813.81m |
| Cost of Revenue | US$405.08m |
| Gross Profit | US$408.73m |
| Other Expenses | US$410.44m |
| Earnings | -US$1.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 50.22% |
| Net Profit Margin | -0.21% |
| Debt/Equity Ratio | 0% |
How did 0A4W perform over the long term?
See historical performance and comparison